Mostrar registro simples

dc.contributor.authorBertoluci, Marcello Casacciapt_BR
dc.contributor.authorMoreira, Rodrigo de Oliveirapt_BR
dc.contributor.authorFaludi, André Arpadpt_BR
dc.contributor.authorIzar, Maria Cristina de Oliveirapt_BR
dc.contributor.authorSchaan, Beatriz D'Agordpt_BR
dc.contributor.authorValerio, Cynthia Melissapt_BR
dc.contributor.authorBertolami, Marcelo Chiarapt_BR
dc.contributor.authorChacra, Ana Paulapt_BR
dc.contributor.authorMalachias, Marcus V. Bolivarpt_BR
dc.contributor.authorVencio, Sérgio Alberto Cunhapt_BR
dc.contributor.authorSaraiva, Jose Francisco Kerrpt_BR
dc.contributor.authorBetti, Roberto Tadeu Barcellospt_BR
dc.contributor.authorTuratti, Luiz Alberto Andreottipt_BR
dc.contributor.authorFonseca, Francisco Antonio Helfensteinpt_BR
dc.contributor.authorBianco, Henrique Triapt_BR
dc.contributor.authorSulzbach, Marthapt_BR
dc.contributor.authorBertolami, Adrianapt_BR
dc.contributor.authorSalles, João Eduardo Nunespt_BR
dc.contributor.authorHohl, Alexandrept_BR
dc.contributor.authorTrujilho, Fábio Rógeriopt_BR
dc.contributor.authorLima, Eduardo Gomespt_BR
dc.contributor.authorMiname, Marcio Hiroshipt_BR
dc.contributor.authorZanella, Maria Terezapt_BR
dc.contributor.authorLamounier, Rodrigopt_BR
dc.contributor.authorSá, João Roberto dept_BR
dc.contributor.authorAmodeo, Celsopt_BR
dc.contributor.authorPires, Antonio Carlospt_BR
dc.contributor.authorSantos Filho, Raul Dias dospt_BR
dc.date.accessioned2017-11-28T02:29:24Zpt_BR
dc.date.issued2017pt_BR
dc.identifier.issn1758-5996pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/170623pt_BR
dc.description.abstractBackground: Since the first position statement on diabetes and cardiovascular prevention published in 2014 by the Brazilian Diabetes Society, the current view on primary and secondary prevention in diabetes has evolved as a result of new approaches on cardiovascular risk stratification, new cholesterol lowering drugs, and new anti-hyperglycemic drugs. Importantly, a pattern of risk heterogeneity has emerged, showing that not all diabetic patients are at high or very high risk. In fact, most younger patients who have no overt cardiovascular risk factors may be more adequately classified as being at intermediate or even low cardiovascular risk. Thus, there is a need for cardiovascular risk stratification in patients with diabetes. The present panel reviews the best current evidence and proposes a practical riskbased approach on treatment for patients with diabetes. Main body: The Brazilian Diabetes Society, the Brazilian Society of Cardiology, and the Brazilian Endocrinology and Metabolism Society gathered to form an expert panel including 28 cardiologists and endocrinologists to review the best available evidence and to draft up-to-date an evidence-based guideline with practical recommendations for risk stratification and prevention of cardiovascular disease in diabetes. The guideline includes 59 recommendations covering: (1) the impact of new anti-hyperglycemic drugs and new lipid lowering drugs on cardiovascular risk; (2) a guide to statin use, including new definitions of LDL-cholesterol and in non-HDL-cholesterol targets; (3) evaluation of silent myocardial ischemia and subclinical atherosclerosis in patients with diabetes; (4) hypertension treatment; and (5) the use of antiplatelet therapy. Conclusions: Diabetes is a heterogeneous disease. Although cardiovascular risk is increased in most patients, those without risk factors or evidence of sub-clinical atherosclerosis are at a lower risk. Optimal management must rely on an approach that will cover both cardiovascular disease prevention in individuals in the highest risk as well as protection from overtreatment in those at lower risk. Thus, cardiovascular prevention strategies should be individualized according to cardiovascular risk while intensification of treatment should focus on those at higher risk.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofDiabetology & metabolic syndrome. London. Vol. 9 (Jul. 2017), 53, 36 f.pt_BR
dc.rightsOpen Accessen
dc.subjectDiabetes mellitusen
dc.subjectDoenças cardiovascularespt_BR
dc.subjectCardiovascular preventionen
dc.subjectDiabetes mellituspt_BR
dc.subjectCardiovascular screeningen
dc.subjectBlood glucoseen
dc.subjectRisk factorsen
dc.subjectCoronary artery diseaseen
dc.subjectDyslipidemiasen
dc.subjectHypertensionen
dc.subjectAntiplatelet agentsen
dc.titleBrazilian guidelines on prevention of cardiovascular disease in patients with diabetes : a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM)pt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001053420pt_BR
dc.type.originEstrangeiropt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples